


# Product Data Sheet

## NVP-BSK805

<b>Cat. No.:</b>	A3675
<b>CAS No.:</b>	1092499-93-8
<b>Formula:</b>	C27H28F2N6O
<b>M.Wt:</b>	490.55
<b>Synonyms:</b>	BSK 805;BSK-805;BSK805;NVP-BSK 805
<b>Target:</b>	Chromatin/Epigenetics
<b>Pathway:</b>	JAK
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

≥20.95 mg/mL in DMSO; ≥3.45 mg/mL in H<sub>2</sub>O with gentle warming and ultrasonic; ≥4.75 mg/mL in EtOH with gentle warming and ultrasonic

In Vitro	Preparing Stock Solutions	Mass			
		Solvent Concentration	1mg	5mg	10mg
		<b>1 mM</b>	2.0385 mL	10.1926 mL	20.3853 mL
		<b>5 mM</b>	0.4077 mL	2.0385 mL	4.0771 mL
		<b>10 mM</b>	0.2039 mL	1.0193 mL	2.0385 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary	ATP-competitive JAK2 inhibitor	
IC <sub>50</sub> & Target	0.5 nM (JAK2)	
In Vitro	<b>Cell Viability Assay</b>	
	Cell Line:	Ba/F3 cells
	Preparation method:	Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

	Reacting conditions:	100 nM; 72 hrs
	Applications:	NVP-BSK805 inhibited the growth of JAK2V617F cells (Ba/F3) and induced apoptosis with a GI50 at concentrations < 100 nM.
In Vivo	<b>Animal experiment</b>	
	Animal models:	RhEpo-induced polycythemia model in female BALB/c mice
	Dosage form:	50, 75 and 100 mg/kg; p.o.; q.d.
	Applications:	At the doses of 25, 50 and 100 mg/kg, NVP-BSK805 suppressed rhEpo-induced STAT5 phosphorylation as well as rhEpo-mediated polycythemia and splenomegaly in BALB/c mice.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1]. Baffert F, Régnier CH, De Pover A, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther, 2010, 9(7): 1945-1955.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



# APEx BIO Technology

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

